taken
half
centuri
select
antibioticresist
bacteria
repres
widespread
threat
human
yet
take
week
month
select
inhibitorresist
immunodefici
virus
treat
patient
esteban
domingo
christof
biebrich
manfr
eigen
john
holland
virus
caus
diseas
human
sinc
ancient
time
earli
bc
viral
diseas
record
hieroglyph
ancient
egypt
evid
smallpox
infect
found
pockmarkscar
remain
pharaoh
rams
v
centuri
earli
write
describ
prevent
inocul
smallpox
viru
began
appear
china
howev
wasnt
pioneer
work
adolf
mayer
dimitri
ivanovski
martinu
beijerinck
tobacco
mosaic
viru
earli
virus
recogn
distinct
pathogen
microorgan
throughout
histori
virus
primarili
play
detriment
role
human
health
smallpox
influenza
virus
caus
worldwid
epidem
result
million
death
prevent
spread
aphthoviru
pathogen
respons
footandmouth
diseas
million
anim
slaughter
result
signific
econom
loss
recent
sar
coronaviru
made
headlin
outbreak
spread
rapidli
across
world
nearpandem
fashion
kill
infect
individu
also
highli
pathogen
influenza
viru
subtyp
often
known
avian
influenza
viru
potenti
pandem
threat
becom
major
global
concern
world
wit
emerg
human
immunodefici
viru
hiv
sinc
hiv
infect
lead
acquir
immunodefici
syndrom
aid
becom
global
crisi
catastroph
proport
infect
nearli
million
new
individu
per
year
effect
treatment
hiv
aid
slow
cours
diseas
cure
vaccin
date
evolut
drug
resist
one
fundament
problem
medicin
hivaid
rapid
emerg
drugresist
variant
major
obstacl
current
treatment
proteas
inhibitor
essenti
compon
present
antiretrovir
therapi
howev
proteas
inhibitor
resist
occur
viral
mutat
alter
inhibitor
bind
result
loss
efficaci
loss
potenc
rais
seriou
question
regard
effect
longterm
antiretrovir
therapi
hivaid
context
research
focus
design
inhibitor
form
extens
hydrogenbond
interact
enzym
backbon
activ
site
limit
proteas
abil
acquir
drug
resist
geometri
catalyt
site
must
conserv
maintain
function
review
examin
underli
principl
enzym
structur
support
backbonebind
concept
effect
mean
combat
drug
resist
highlight
applic
recent
work
antivir
proteas
inhibitor
hiv
time
line
began
earli
viru
first
isol
sinc
million
individu
throughout
world
infect
hiv
result
onset
aid
swept
across
contin
caus
estim
million
death
leav
million
children
orphan
recent
estim
joint
unit
nation
program
hivaid
unaid
indic
worldwid
million
adult
children
current
live
diseas
million
aidsrel
death
occur
year
statist
alarm
signific
advanc
hiv
treatment
prevent
appear
turn
tide
fight
aid
evidenc
steadili
decreas
number
annual
death
intens
research
develop
novel
antivir
agent
use
multidrug
combin
therapi
result
signific
increas
life
expect
access
therapi
unfortun
rapid
emerg
drug
resist
render
mani
treatment
ineffect
continu
formid
challeng
molecular
design
drug
discoveri
moreov
consequ
drug
resist
may
unravel
progress
made
toward
hivaid
manag
today
still
urgent
need
develop
novel
antihiv
therapeut
drugdesign
tool
combat
drug
resist
biochem
event
critic
hiv
replic
suggest
number
drugdesign
target
therapeut
intervent
among
hiv
proteas
enzym
quickli
recogn
import
therapeut
target
demonstr
effect
hiv
proteas
essenti
product
matur
infecti
hiv
virion
logic
inhibit
hiv
proteas
becam
subject
much
pharmaceut
research
subsequ
drugdevelop
effort
led
advent
first
gener
proteas
inhibitor
pi
mark
new
era
aid
chemotherapi
use
pi
combin
revers
transcriptas
inhibitor
prove
extrem
effect
treatment
regimen
suppress
viral
reproduct
reduc
possibl
viral
mutat
despit
earli
success
pi
plagu
sever
drawback
includ
low
metabol
stabil
poor
bioavail
debilit
side
effect
drug
toxic
perhap
concern
obstacl
rapid
develop
drugresist
viral
strain
render
pi
ineffect
current
patient
achiev
initi
viral
suppress
eventu
experi
treatment
failur
addit
drugresist
viral
strain
transmit
new
individu
success
futur
manag
hivaid
depend
develop
new
antivir
agent
maintain
efficaci
drugresist
viral
strain
astonish
capac
genet
evolut
major
drive
forc
drug
resist
relentless
abil
mutat
aris
high
mismatch
error
rate
nucleotid
base
per
cycl
viruss
revers
transcriptas
enzym
absenc
exonucleasebas
proofread
activ
factor
conjunct
viruss
rapid
replic
cycl
virion
per
day
genet
recombin
abil
result
seemingli
endless
genet
diversif
howev
number
variant
within
quasispeci
given
time
limit
natur
select
deleteri
mutat
limit
host
cell
avail
inactiv
host
immun
system
respons
result
viru
popul
primarili
consist
singlemut
strain
rel
doublemut
strain
antiretrovir
treatment
creat
new
select
pressur
result
amplif
drugresist
strain
viral
evolut
continu
time
ad
new
mutat
restor
viral
fit
maintain
drug
resist
lead
resurg
viral
load
eventu
treatment
failur
combat
drug
resist
remain
formid
challeng
must
consid
design
new
antiretrovir
agent
may
effect
develop
therapi
limit
emerg
growth
variant
combat
variant
alreadi
evolv
develop
new
class
antiretrovir
drug
new
mechan
action
show
durabl
effect
caus
minim
side
effect
import
therapeut
object
reason
optimist
tremend
progress
made
term
new
drug
potent
high
genet
barrier
resist
recent
number
new
approv
drug
novel
mechan
action
includ
integras
inhibitor
virusentri
inhibitor
shown
efficaci
resist
strain
howev
drug
quickli
succumb
develop
resist
render
ineffect
also
matur
inhibit
smallmolecul
inhibit
hiv
premrna
splice
hold
consider
promis
evolut
hiv
proteas
respons
therapeut
pressur
review
great
detail
present
briefli
hiv
proteas
mutat
aris
respons
treatment
condit
must
definit
provid
replic
advantag
primari
mutat
typic
includ
commonli
found
near
activ
site
affect
hydrophob
van
der
waal
electrostat
interact
enzym
inhibitor
result
loss
bind
affin
decreas
inhibitor
drug
effect
howev
mutat
also
interfer
substrat
process
confer
fit
cost
neg
affect
replic
hiv
result
addit
mutat
accumul
stepwis
fashion
restor
catalyt
effici
maintain
drug
resist
often
secondari
mutat
occur
away
activ
site
caus
longrang
structur
perturb
compens
primari
mutat
function
deficit
addit
gag
gagpol
may
coevolv
proteas
incur
mutat
enhanc
abil
process
mutant
proteas
ultim
ten
mutat
accumul
result
viabl
virus
resist
multipl
drug
target
protein
backbon
combat
drug
resist
develop
novel
structurebas
concept
drug
design
address
problem
drug
resist
structur
analysi
comparison
xray
structur
variou
mutant
proteas
xray
structur
wildtyp
proteas
reveal
backbon
conform
activ
site
mutant
proteas
minim
distort
conceiv
design
inhibitor
maxim
interact
hiv
proteas
activ
site
particularli
extens
hydrogenbond
interact
protein
backbon
wildtyp
proteas
inhibitor
like
maintain
contact
mutant
proteas
essenc
target
protein
backbon
develop
drugresist
hiv
hinder
mutat
alter
backbon
conform
would
like
reduc
catalyt
capac
view
design
inhibitor
molecular
crab
capabl
tightli
grip
protein
backbon
hold
enzym
activ
site
backbonebind
design
strategi
led
develop
new
pi
enhanc
activesit
interact
particular
inhibitorbackbon
hydrogenbond
interact
fundament
drug
resist
occur
viral
mutat
must
aris
diminish
drug
bind
retain
viral
fit
mutat
occur
within
activ
site
result
structur
distort
limit
produc
impair
proteolysi
natur
polyprotein
substrat
reinforc
review
xray
structur
mutant
proteas
reveal
structur
chang
associ
drugresist
mutant
base
upon
backbonebind
strategi
focus
molecular
design
effort
promot
extens
hydrogenbond
interact
protein
backbon
atom
contribut
subsit
subsit
larg
form
hydrophob
residu
hydrophob
hydrophil
residu
contribut
subsit
addit
plan
fill
hydrophob
pocket
throughout
proteas
activ
site
thu
limit
abil
viru
develop
drug
resist
furthermor
sought
improv
bioavail
decreas
peptid
charact
inhibitor
design
heterocycl
cyclicpolyetherderiv
templat
ligand
review
highlight
molecular
drug
design
angewandt
chemi
basi
target
proteinbackbonebind
concept
featur
design
inhibitor
emerg
novel
design
concept
extens
xray
crystallograph
studi
detail
analysi
antivir
data
strongli
corrobor
proteinbackbonebind
strategi
combat
drug
resist
investig
factor
control
enzym
activ
reveal
protein
structur
enzym
function
close
relat
enzym
protein
consist
strand
amino
acid
combin
form
distinct
polypeptid
chain
protein
fold
spontan
gener
local
secondari
structur
helix
b
strand
etc
lead
format
defin
threedimension
tertiari
structur
mani
enzym
multipl
protein
chain
combin
noncoval
interact
form
quaternari
structur
possess
multipl
subunit
protein
structur
stabil
collect
weak
intramolecular
forc
disrupt
reform
allow
limit
rang
dynam
movement
fold
process
creat
caviti
near
surfac
enzym
may
serv
substrat
bind
site
interestingli
rel
small
volum
overal
enzym
constitut
activ
catalyt
site
remaind
protein
serv
structur
scaffold
effect
catalysi
occur
amino
acid
residu
within
activ
site
requir
specif
configur
transit
state
chemic
reaction
attain
readili
absenc
enzym
perturb
configur
deleteri
effect
result
loss
catalyt
function
henc
viral
mutat
limit
natur
select
requir
maintain
key
structur
element
enzym
activ
site
proteas
aspart
proteas
contain
two
catalyt
aspart
acid
residu
activ
site
share
acid
proton
interact
water
molecul
absenc
substrat
inhibitor
catalyt
activ
enzym
homo
dimer
monom
compris
amino
acid
activ
site
form
two
catalyt
aspart
acid
residu
locat
domain
monom
scissil
bond
peptid
substrat
close
proxim
activ
site
pair
flap
one
monom
locat
entranc
activ
site
flap
fold
substrat
upon
bind
act
solvent
shield
exclud
water
creat
local
environ
conduc
catalysi
flap
flexibl
show
open
conform
apoenzym
peptid
substrat
contain
least
seven
residu
extend
scissil
bond
lie
side
chain
substrat
lie
subsit
form
proteas
residu
hydrophob
residu
occupi
subsit
hydrophob
hydrophil
residu
accommod
subsit
seri
conserv
hydrogenbond
interact
connect
backbon
proteas
substrat
serv
major
contribut
bind
affin
interact
shown
figur
xray
structur
hiv
proteas
bound
peptid
analogu
cleavag
site
pdb
code
demonstr
interact
number
amino
acid
residu
activ
site
highli
conserv
therefor
inhibitor
design
strategi
target
residu
led
potent
pi
effort
structurebas
drug
design
develop
novel
antivir
proteas
inhibitor
cyan
proteas
complex
substrat
analogu
pdb
code
magenta
show
close
conform
flap
catalyt
residu
peptid
analogu
shown
stick
model
b
interact
proteas
peptid
analogu
cleavag
site
acethrilenlernleglnarg
nle
norleucin
substitut
met
natur
peptid
sequenc
r
indic
reduc
peptid
bond
pdb
code
conserv
hydrogenbond
interact
shown
green
dot
line
nonconserv
hydrogen
bond
indic
black
dash
line
wwwangewandteorg
compar
xray
crystal
structur
inhibitorbound
proteas
wild
type
crystal
structur
drugresist
mutant
proteas
state
earlier
superimposit
structur
indic
minim
deviat
backbon
atom
around
activ
site
structur
comparison
provid
insight
molecular
design
strategi
combat
drug
resist
review
recent
mutat
divid
two
main
categori
first
mutat
activesit
residu
directli
alter
proteas
interact
inhibitor
shown
exampl
mutant
contain
reduc
interact
number
pi
altern
distal
mutat
act
indirectli
diminish
proteas
stabil
interact
inhibitor
shown
mutant
major
mutant
show
minim
chang
backbon
structur
around
activ
site
even
flexibl
flap
gener
show
chang
less
backbon
atom
one
except
mutat
produc
shift
loop
compris
residu
compens
hydrophob
contact
loop
adjust
accommod
differents
hydrophob
group
inhibitor
depict
figur
even
structur
drugresist
proteas
mutat
proteas
differ
differ
residu
superimpos
minim
deviat
backbon
atom
around
activ
site
mutat
produc
drug
resist
significantli
alter
overal
structur
activ
site
essenti
proteas
function
viabl
mutant
strain
show
minim
distort
structur
proteas
activ
site
expect
order
maintain
catalyt
activ
viral
replic
fit
base
observ
hypothes
inhibitor
maxim
hydrogenbond
interact
backbon
nh
c
atom
activ
site
would
retain
interact
viral
mutant
therefor
compound
would
maintain
potenc
despit
viral
mutat
provid
viabl
solut
problem
drug
resist
treatment
use
origin
design
concept
activ
design
synthes
varieti
inhibitor
form
extens
bind
interact
proteas
backbon
capabl
maintain
efficaci
panel
clinic
relev
drugresist
viral
strain
structurebas
design
target
protein
backbon
effort
combat
drug
resist
involv
design
synthesi
conceptu
novel
proteas
inhibitor
base
upon
xray
structur
proteas
bound
saquinavir
figur
major
strategi
structurebas
design
maxim
inhibitor
interact
proteas
activ
site
particularli
plan
promot
hydrogen
bond
proteas
backbon
atom
subsit
effort
culmin
discoveri
wide
rang
exceedingli
potent
pi
impress
resist
profil
one
pi
darunavir
approv
fda
treatment
hivaid
patient
harbor
drugresist
hiv
describ
develop
darunavir
number
recent
review
briefli
highlight
earli
structurebas
effort
focu
mainli
darunavir
uniqu
bind
properti
use
xray
crystallograph
studi
analyz
drugresist
properti
light
structur
inform
provid
highlight
subsequ
effort
design
varieti
pi
use
backbonebind
strategi
develop
new
gener
pi
withstand
emerg
multidrugresist
variant
initi
design
pi
focus
reduc
peptidelik
featur
improv
druglik
properti
saquinavirbas
proteas
inhibitor
saquinavir
potent
fdaapprov
inhibitor
establish
structureact
studi
known
xray
structur
inform
provid
import
molecular
insight
ligandbind
interact
basi
structur
inform
particularli
interest
reduc
molecular
weight
elimin
peptidelik
bond
drew
inspira
figur
overlay
proteas
multipl
mutant
green
pdb
code
yellow
pdb
code
proteas
red
pdb
code
proteas
blue
pdb
code
show
minim
backbon
deviat
chemi
tion
natur
began
incorpor
cyclic
ether
featur
inher
bioactiv
natur
product
develop
seri
molecular
scaffold
featur
conform
constrain
cyclic
ether
heterocycl
structur
mimic
bind
mode
peptideamid
bond
subsit
proteas
activ
site
although
saquinavir
potent
pi
oral
bioavail
poor
possibl
presenc
multipl
amid
peptid
bond
base
upon
xray
structur
saquinavirbound
proteas
attempt
replac
two
amid
carbonyl
cyclic
ether
sulfon
templat
particularli
plan
posit
ether
sulfon
oxygen
atom
could
form
interact
proteas
similar
seen
amid
peptid
carbonyl
function
saquinavir
interest
cyclic
ether
featur
numer
bioactiv
natur
product
contain
structur
subunit
natur
product
monensin
ginkolid
suffer
absorpt
problem
inher
peptidelik
drug
shown
figur
replac
saquinavir
glycin
result
potent
pi
enzym
ic
nm
antivir
cic
nm
r
configur
appear
critic
potenc
remov
ligand
design
correspond
stereochem
defin
urethan
deriv
ic
nm
concentr
inhibit
cell
cultur
cic
nm
lead
structur
quit
import
molecular
weight
da
much
less
saquinavir
da
urethan
significantli
potent
correspond
nboc
deriv
incorpor
function
hydroxyethylenederiv
inhibitor
result
mark
enhanc
enzym
inhibitori
antivir
activ
correspond
nboc
deriv
cyclopentyl
deriv
figur
significantli
less
activ
even
though
pi
presum
fill
substrat
bind
site
fashion
inhibitor
result
indic
cyclic
ether
oxygen
import
preliminari
xray
structur
proteas
show
thfring
oxygen
involv
weak
hydrogenbond
interact
nh
group
introduct
urethan
hydroxyethylamin
sulfonamid
isoster
develop
vasquez
et
al
tung
et
al
result
pi
figur
subsequ
develop
fdaapprov
inhibitor
amprenavirfosamprenavir
xray
structur
proteas
indic
ring
fill
subsit
ring
oxygen
involv
weak
interact
backbon
amid
distanc
respect
base
upon
preliminari
develop
urethan
possibl
substitut
ligand
saquinavir
becam
interest
enhanc
bindingsit
interact
subsit
object
ultim
led
us
design
stereochem
defin
bicycl
tetrahydrofuran
bisthf
ligand
shown
figur
inhibitor
bisthf
ligand
significantli
potent
inhibitor
contain
bisthf
ligand
inhibitor
also
consider
potent
inhibitor
ligand
xray
crystallograph
studi
reveal
bisthf
oxygen
form
effect
hydrogen
bond
backbon
nh
group
furthermor
xray
structur
show
bicycl
ring
fill
hydrophob
pocket
site
effect
monocycl
inhibitor
interest
wwwangewandteorg
ingli
howev
inhibitor
form
hydrogen
bond
protein
backbon
site
state
earlier
combat
drug
resist
main
emphasi
backbonebind
strategi
maxim
ligand
bind
site
interact
especi
promot
hydrogenbond
format
backbon
atom
subsit
proteas
follow
design
highaffin
nonpeptid
bisthf
ligand
next
object
design
inhibitor
could
form
robust
hydrogen
bond
throughout
subsit
investig
effect
bisthf
ligand
number
differ
isoster
includ
r
hydroxyethyl
sulfonamid
isoster
pmethoxysulfonamid
ligand
initi
choic
pmethoxysulfonamid
base
upon
presumpt
methoxi
oxygen
would
form
effect
hydrogen
bond
backbon
nh
group
subsit
shown
figur
inhibitor
uicpi
later
exhibit
mark
enzym
inhibitori
potenc
k
pm
antivir
activ
id
nm
cem
cell
line
obtain
molecular
insight
ligand
bind
site
interact
highresolut
xray
structur
proteas
determin
shown
figur
oxygen
atom
bisthf
ligand
form
strong
hydrogen
bond
backbon
nh
group
subsit
subsit
pmethoxi
oxygen
also
form
strong
hydrogen
bond
backbon
nh
group
well
carboxyl
side
chain
inhibitori
potenc
numer
mutant
hiv
proteas
determin
shown
tabl
inhibitor
maintain
impress
potenc
k
pm
k
mut
k
wt
ratio
greater
indic
proteas
multipl
mutat
shown
highli
resist
approv
firstgener
pi
display
low
level
resist
inhibitor
also
maintain
excel
potenc
wide
spectrum
drugresist
variant
ic
valu
rang
nm
shown
tabl
detail
drugsensit
evalu
demonstr
signific
advantag
compar
structur
relat
amprenavir
approv
pi
term
emerg
drug
resist
interestingli
viral
acquisit
resist
substanti
delay
furthermor
hiv
remain
sensit
approv
pi
except
amprenavir
notabl
inhibitor
retain
impress
potenc
ic
nm
multipiresist
strain
isol
patient
harbor
drugresist
specul
impress
activ
wide
spectrum
drugresist
hiv
variant
robust
bind
properti
activ
site
particularli
extens
interact
backbon
nh
group
aspart
subsit
thu
backbonebind
strategi
promot
extens
hydrogen
bond
throughout
activ
site
subsit
may
intrigu
conceptu
framework
design
new
gener
pi
combat
drug
resist
base
upon
result
inhibitor
explor
combin
bisthf
ligand
r
hydroxyethyl
sulfonamid
isoster
varieti
sulfonamid
function
ligand
chosen
interact
backbon
atom
site
effort
led
design
synthesi
number
except
potent
pi
howev
inhibitor
figur
later
name
darunavir
exhibit
improv
pharmacolog
properti
drugresist
profil
attribut
uniqu
bind
profil
main
contribut
factor
antivir
profil
led
us
establish
design
concept
proteinbackbon
bind
promis
strategi
overcom
drug
resist
follow
section
take
closer
look
bind
darunavir
uniqu
antivir
profil
darunavir
enhanc
bind
affin
k
pm
like
relat
abil
form
extens
network
hydrogenbond
interact
within
proteas
activ
site
highresolut
xray
crystal
structur
darunavirbound
proteas
reveal
number
key
interact
darunavir
proteas
backbon
atom
shown
figur
bisthf
ligand
form
strong
hydrogen
bond
backbon
amid
nh
group
anchor
darunavir
subsit
opposit
end
darunavir
paminosulfonamid
interact
amid
carboxyl
acid
side
chain
therebi
stabil
darunavir
within
activ
site
hydroxi
group
hydroxyethyl
sulfonamid
isoster
serv
transitionst
mimic
form
hydrogen
bond
catalyt
residu
addit
urethan
nh
group
interact
carbonyl
tetracoordin
water
molecul
form
hydrogen
bond
flap
residu
urethan
carbonyl
sulfonamid
oxygen
darunavir
isobutyl
benzyl
group
darunavir
enhanc
bind
hydrophob
interact
multipl
bind
interact
allow
darunavir
act
molecular
crab
tightli
clutch
protein
backbon
unlik
mani
firstgener
pi
bind
darunavir
proteas
uniqu
exampl
bind
mani
pi
driven
entrop
gain
bind
darunavir
highli
enthalp
favor
possibl
numer
hydrogenbond
interact
anoth
notic
differ
lie
kinet
darunavir
bind
proteas
show
high
associ
rate
amino
acid
substitut
identifi
proteaseencod
region
virus
compar
consensu
sequenc
cite
lo
alamo
databas
see
refer
detail
figur
darunavir
bind
proteas
like
molecular
crab
pdb
code
slow
dissoci
rate
much
lower
pi
togeth
attribut
provid
darunavir
specif
highaffin
bind
profil
except
abil
accommod
proteas
mutat
final
distinguish
characterist
darunavir
capabl
bind
proteas
second
locat
indic
recent
xray
analysi
second
bind
site
lie
surfac
proteas
one
flexibl
flap
alloster
bind
locat
may
contribut
darunavir
except
antivir
activ
inhibit
function
proteas
studi
examin
kinet
darunavir
bind
suggest
mixedtyp
competitiveuncompetit
inhibit
model
contrast
firstgener
pi
exhibit
strictli
competit
inhibit
result
consist
second
bind
site
darunavir
like
contribut
darunavir
heighten
antivir
activ
profil
darunavir
demonstr
remark
antivir
potenc
across
broad
rang
viral
strain
depict
tabl
panel
isol
darunavir
outperform
mani
approv
pi
inhibit
viral
replic
infect
ic
nm
darunavir
potent
antivir
activ
combin
rel
low
cytotox
provid
elev
select
index
cc
ec
importantli
darunavir
consist
retain
impress
antivir
activ
host
viral
strain
resistancerel
mutat
notabl
darunavir
exert
impress
activ
highli
multipiresist
clinic
variant
isol
patient
aid
respond
exist
antivir
regimen
result
shown
tabl
darunavir
exhibit
excel
antivir
activ
ic
valu
rang
nm
apv
idv
nfv
rtv
virtual
ineffect
block
replic
multipiresist
strain
also
survey
panel
laboratori
strain
select
resist
pi
darunavir
maintain
excel
activ
tabl
apvresist
viral
strain
display
crossresist
darunavir
explain
fact
apv
contain
sulfonamid
isoster
similar
darunavir
elabor
studi
util
broad
rang
clinic
isol
confirm
darunavir
remark
properti
darunavir
maintain
ec
less
nm
variant
show
less
tenfold
chang
ec
compar
wildtyp
strain
contrast
apv
sqv
idv
rtv
nfv
lpv
display
ed
valu
nm
less
viral
strain
show
significantli
higher
level
variabl
ec
valu
compar
wildtyp
major
challeng
treatment
hiv
remain
rapid
emerg
drug
resist
reduc
effect
antivir
treatment
promin
attribut
darunavir
set
apart
pi
high
genet
barrier
develop
viral
resist
earli
attempt
select
darunavirresist
hiv
virus
vitro
prove
difficult
resist
develop
slowli
bal
pbmc
rod
eho
assay
conduct
duplic
triplic
data
repres
mean
ic
valu
three
independ
experi
ic
evalu
phapbmc
inhibit
gag
protein
product
drug
end
point
cell
expos
viru
cultur
ic
valu
determin
mtt
assay
see
refer
detail
chemi
multipl
passag
concentr
less
nm
darunavir
figur
later
studi
show
although
wildtyp
hiv
viru
propag
darunavir
resist
easili
isol
antiretroviralexperienc
patient
capabl
acquir
resistancerel
mutat
power
clinic
trial
amino
acid
substitut
correl
darunavir
resist
includ
consid
major
mutat
later
identifi
amino
acid
substitut
distinctli
associ
darunavir
caus
pi
result
signific
reduct
enzym
fit
restor
part
secondari
mutat
darunavir
resist
believ
occur
shift
posit
sulfonamid
alter
abil
hydrogen
bond
proteas
caus
decreas
bind
affin
darunavir
impress
antivir
profil
attribut
part
small
flexibl
conform
abil
form
extens
hydrogenbond
interact
proteas
backbon
impart
high
bind
affin
anoth
contribut
factor
darunavir
uniqu
abil
act
dual
inhibitor
block
cleavag
natur
peptid
substrat
also
inhibit
dimer
proteas
activ
proteas
consist
two
chain
amino
acid
combin
dimer
singl
catalyt
activ
quaternari
structur
dimer
monom
subunit
essenti
activ
thu
inhibit
repres
distinct
mechan
inhibit
viral
replic
darunavir
block
dimer
process
concentr
low
mm
investig
current
ongo
tpv
pi
besid
darunavir
shown
possess
properti
capabl
block
dimer
individu
monom
neither
darunavir
tpv
abl
caus
disassoci
assembl
proteas
unit
except
potent
bisthfderiv
pi
continu
explor
structur
modif
would
form
addit
hydrogen
bond
proteas
backbon
residu
lead
inhibitor
higher
affin
incorpor
benzodioxolan
sulfonamid
ligand
provid
inhibitor
shown
figur
turn
exceedingli
potent
inhibitor
signific
antivir
activ
k
pm
ic
nm
seen
tabl
inhibitor
evalu
wide
spectrum
multidrugresist
clinic
isol
inhibitor
outperform
approv
pi
includ
darunavir
maintain
signific
antivir
activ
chang
similar
darunavir
furthermor
evalu
piresist
variant
found
uniqu
antivir
activ
profil
tabl
piresist
variant
crossresist
apv
observ
interestingli
sqv
atv
remain
activ
viral
strain
select
contain
mutat
link
resist
result
signific
loss
fit
proteas
determin
crystal
structur
proteas
resolut
structur
provid
import
molecular
insight
inhibitor
potenc
cell
expos
strain
tcid
inhibit
gag
protein
product
drug
use
end
point
number
parenthes
repres
fold
chang
ic
valu
isol
rel
see
refer
drugresist
profil
structur
analys
reveal
involv
extens
interact
backbon
atom
amino
acid
proteas
activ
site
figur
subsit
interact
import
potenc
widespectrum
activ
multipiresist
variant
moreov
interact
maintain
crystal
structur
drugresist
mutant
comparison
crystal
structur
crystal
structur
darunavir
figur
show
interact
site
similar
natur
hydrogen
bond
residu
differ
region
watermedi
interact
one
benzodioxolan
oxygen
flap
residu
observ
darunavir
differ
interact
may
account
improv
ic
valu
compar
darunavir
numer
potent
pi
design
base
upon
privileg
bisthf
ligand
shown
figur
brecanavir
develop
glaxo
smith
kline
contain
bisthf
ligand
benzodioxolan
ligand
substitut
ligand
show
femtomolar
enzym
inhibitori
potenc
k
fm
subnanomolar
antivir
activ
ic
valu
nm
wildtyp
viru
also
bcv
exhibit
ic
valu
nm
nm
two
mdr
viral
strain
respect
bcv
exhibit
subto
figur
structur
xray
crystal
structur
proteas
amino
acid
substitut
identifi
proteaseencod
region
compar
consensu
type
b
sequenc
cite
lo
alamo
databas
see
refer
detail
b
effect
concentr
cell
expos
tcid
dose
infect
cell
cultur
inhibit
gag
protein
product
drug
use
end
point
number
parenthes
repres
nfold
chang
ec
valu
isol
compar
ec
valu
wildtyp
assay
conduct
duplic
triplic
data
shown
deriv
result
three
independ
experi
nd
determin
see
refer
detail
chemi
low
nanomolar
ic
valu
low
crossresist
panel
highli
resist
specif
piresist
isol
furthermor
bcv
test
panel
clinic
isol
piexperienc
patient
maintain
low
nanomolar
ic
valu
nm
isol
major
isol
display
ic
valu
nm
inhibitor
undergon
clinic
develop
phase
iii
level
howev
brecanavir
clinic
trial
termin
formul
issu
investig
structurebas
modif
side
chain
inhibitor
particular
interest
attempt
incorpor
basic
amin
cyclic
ether
function
improv
aqueou
solubl
pharmacolog
properti
pi
shown
potent
antivir
activ
inhibitor
contain
bisthf
unit
pmethoxybenzesulfonamid
ligand
diethylphosphonylmethoxi
group
attach
phenyl
ligand
develop
research
gilead
scienc
phosphon
function
design
promot
better
intracellular
retent
without
interf
proteas
bind
site
pi
display
excel
resist
profil
exhibit
mean
chang
ec
valu
rang
nm
wildtyp
hiv
inhibitor
display
mean
chang
nm
chang
ec
valu
nm
compar
darunavir
bcv
respect
toward
possibl
explan
mark
resist
suppress
propos
phosphon
moieti
act
anchor
point
solvent
medium
enhanc
degeneraci
bind
state
inhibitor
provid
favor
entrop
compens
follow
proteas
mutat
interestingli
select
strain
expos
exhibit
sign
ram
resistanceassoci
mutat
even
six
month
report
show
favor
pharmacolog
metabol
profil
pi
xray
crystal
structur
proteas
bind
profil
bisthf
methoxysulfonamid
ligand
similar
observ
xray
structur
proteas
comparison
two
structur
show
one
phosphon
ethyl
moieti
bound
hydrophob
cleft
surfac
proteas
pdiethylphosphon
phenyl
residu
exhibit
better
resist
profil
bcv
contain
substitut
methylthiazol
proteas
flap
flexibl
apoenzym
form
close
inhibitor
bind
show
minim
chang
backbon
conform
seen
figur
novel
watermedi
interact
benzodioxolan
oxygen
may
respons
superb
antivir
drugresist
profil
base
upon
xray
structur
proteas
envis
heteroatomcontain
substitu
posit
bisthf
ligand
would
ideal
posit
interact
backbon
nh
group
therefor
synthes
seri
new
pi
incorpor
bisthf
ligand
shown
figur
inhibitor
group
better
enzym
inhibitori
potenc
k
pm
inhibitor
k
pm
isom
potent
correspond
isom
larger
alkyl
group
benzyloxi
substitu
led
signific
reduct
potenc
xray
structur
proteas
figur
show
extens
interact
inhibitor
proteas
activ
site
similar
inhibitor
howev
appear
oxygen
group
form
uniqu
watermedi
hydrogen
bond
nh
group
improv
bind
affin
may
due
watermedi
hydrogen
bond
backbon
nh
group
effort
fill
hydrophob
pocket
subsit
flexibl
macrocycl
investig
bisthfderiv
macrocycl
inhibitor
involv
ligand
retain
major
hydrogenbond
interact
protein
backbon
similar
inhibitor
darunavir
effect
fill
hydrophob
pocket
subsit
design
percept
macrocycl
evolv
observ
certain
mutat
lead
decreas
van
der
waal
interact
increas
size
hydrophob
pocket
subsit
structur
studi
indic
mutant
result
decreas
van
der
waal
interact
phenyl
ring
subsit
also
evid
repack
inhibitor
side
chain
proteas
atom
subsit
base
upon
insight
envis
satur
unsatur
macrocycl
would
effect
fill
subsit
shown
figur
macrocycl
inhibitor
display
excel
enzym
inhibitori
antivir
activ
howev
acycl
homologu
significantli
less
potent
also
satur
inhibitor
less
activ
unsatur
analogu
ascertain
structur
effect
led
improv
drugresist
properti
inhibitor
evalu
panel
clinic
wildtyp
x
isol
along
variou
multidrugresist
clinic
x
r
isol
use
pbmc
target
cell
shown
tabl
potenc
inhibitor
ic
nm
respect
superior
approv
inhibitor
idv
apv
lpv
nearli
twofold
less
potent
darunavir
ic
nm
inhibitor
show
better
potenc
amprenavir
drc
drg
drtm
drjsl
six
time
potent
drmm
inhibitor
also
display
superior
potenc
drc
drg
greater
respect
compar
amprenavir
furthermor
macrocycl
pi
prevent
replic
variant
select
mm
saquinavir
lopinavir
indinavir
ic
valu
nm
nm
determin
xray
crystal
structur
proteas
resolut
seen
figur
ligand
involv
extens
hydrogen
amino
acid
substitut
identifi
proteaseencod
region
compar
consensu
type
b
sequenc
cite
lo
alamo
databas
see
refer
detail
angewandt
chemi
bond
interact
protein
backbon
atom
subsit
similar
inhibitor
crownshap
nice
fill
pocket
interestingli
macrocycl
act
less
like
spring
push
phenyl
ring
caus
rotat
toward
along
backbon
absent
xray
structur
proteas
macrocycl
pi
abl
maintain
excel
potenc
multidrugresist
clinic
isol
possibl
abil
make
extens
hydrogen
bond
proteas
backbon
well
hydrophob
interact
subsit
probe
backbonebind
concept
design
strategi
combat
drug
resist
investig
merit
target
protein
backbon
design
strategi
base
upon
variou
proteinligand
xray
structur
decid
design
structur
differ
cyclicetherderiv
ligand
relat
bisthf
ligand
effort
led
design
stereochem
defin
bicycl
hexahydrocyclopentanofuran
cpthf
ligand
incorpor
ligand
hydroxyethylaminosulfonamid
isoster
provid
seri
except
potent
pi
posit
cyclic
ether
oxygen
cpthf
ring
form
hydrogen
bond
backbon
nh
group
seen
figur
replac
bisthf
darunavir
new
cpthf
ligand
provid
inhibitor
exhibit
subnanomolar
enzym
inhibitori
potenc
nearli
ten
time
less
darunavir
k
pm
believ
bind
cpthf
ligand
subsit
distinct
bisthf
ligand
may
caus
slight
shift
posit
remaind
inhibitor
structur
within
activ
site
specul
modif
anilin
could
allow
improv
interact
nh
group
subsit
shown
incorpor
hydroxymethylsulfonamid
ligand
result
inhibitor
show
improv
enzym
inhibit
k
pm
compar
addit
shown
impress
antivir
potenc
ic
nm
similar
inhibitor
order
probe
import
cpthf
ring
oxygen
synthes
inhibitor
oxygen
replac
methylen
group
interestingli
display
loss
enzym
inhibitori
potenc
compar
furthermor
exhibit
drastic
loss
antivir
activ
ic
nm
result
indic
cpthf
ring
oxygen
involv
critic
interact
activ
site
determin
xray
crystal
structur
proteas
resolut
highresolut
structur
provid
critic
molecular
insight
interact
ligand
bind
site
shown
figur
inhibitor
make
extens
interact
activ
site
similar
darunavir
hydroxi
group
form
strong
hydrogen
bond
backbon
nh
group
watermedi
contact
side
chain
oxygen
ring
oxygen
cpthf
ligand
form
strong
hydrogen
bond
backbon
nh
group
weak
hydrogen
bond
interact
wwwangewandteorg
occur
inhibitor
lack
ring
oxygen
may
explain
significantli
less
potent
result
illustr
import
form
hydrogen
bond
proteas
backbon
subsit
suggest
simpli
fill
bind
space
site
suffici
induc
tight
bind
elicit
biolog
respons
superimpos
xray
structur
proteas
wildtyp
three
highli
mutat
drugresist
proteas
structur
show
minim
rootmeansquar
deviat
acarbon
backbon
atom
suggest
inhibitor
retain
good
excel
contact
backbon
mutant
proteas
turn
inhibitor
exert
potent
activ
isol
lai
bal
cell
phapbmc
tabl
furthermor
evid
tabl
inhibitor
retain
signific
antivir
activ
panel
drugresist
viral
strain
inhibitor
display
potent
activ
ic
nm
clinic
strain
et
isol
drugnaiv
patient
furthermor
six
drugresist
clinic
strain
contain
amino
acid
substitut
associ
proteas
inhibitor
resist
b
c
g
tm
ev
es
isol
patient
infect
receiv
differ
antivir
agent
month
test
approv
pi
highli
resist
howev
inhibitor
exert
highli
potent
activ
six
variant
ic
valu
rang
nm
nm
inhibitor
also
highli
potent
k
ic
valu
low
nm
data
indic
inhibitor
highli
activ
wide
spectrum
drugresist
variant
design
ligand
seen
oxygen
atom
cpthf
ring
critic
superb
antivir
antidrugresist
properti
base
upon
xray
structur
proteas
specul
correspond
ligand
would
abl
maintain
interact
similar
cpthf
ligand
essenti
would
insert
oxygen
atom
cpthf
ring
form
ligand
would
greatli
reduc
stereochem
complex
allow
simplifi
synthet
pathway
addit
synthet
advantag
postul
addit
ether
oxygen
may
engag
hydrogenbond
interact
proteas
therebi
enhanc
potenc
pi
figur
depict
structur
potenc
number
pi
incorpor
meso
ligand
syn
isom
demonstr
enzym
inhibitori
potenc
antivir
activ
compar
cpthfderiv
pi
wherea
anti
isom
show
threefold
decreas
potenc
unlik
result
cpthf
ligand
incorpor
hydroxymethyl
group
ligand
result
slight
reduct
potenc
next
explor
ligand
result
inhibitor
exhibit
signific
reduct
antivir
potenc
larger
trioxepan
system
also
provid
less
activ
pi
evalu
panel
multidrugresist
variant
result
shown
tabl
inhibitor
exhibit
antivir
activ
compar
approv
pi
sqv
apv
outperform
idv
howev
activ
darunavir
wildtyp
drugresist
clinic
variant
determin
xray
structur
proteas
resolut
figur
inhibitor
bind
extens
interact
proteas
activ
site
interestingli
one
dioxan
oxygen
form
hydrogen
bond
backbon
nh
group
oxygen
involv
watermedi
hydrogen
bond
amid
nh
group
interact
similar
report
sever
peptid
substrat
analogu
angewandt
chemi
ever
interact
previous
util
ligand
design
base
upon
xray
structur
creat
activ
model
appear
smaller
form
addit
hydrogen
bond
backbon
nh
group
addit
hydrogen
bond
may
explain
increas
antivir
activ
rel
describ
mesodioxolanederiv
inhibitor
exhibit
potent
enzym
inhibitori
antivir
activ
shown
figur
specul
oxygen
dioxolan
ring
form
hydrogen
bond
backbon
nh
group
also
form
watermedi
hydrogen
bond
backbon
nh
group
base
upon
possibl
interact
ligand
bind
site
subsequ
design
deriv
interact
nh
group
flap
synthes
stereochem
defin
alkoxycpthf
deriv
convert
pi
shown
figur
seen
inhibitor
group
show
potent
antivir
activ
compar
amino
acid
substitut
identifi
proteaseencod
region
compar
consensu
type
b
sequenc
cite
lo
alamo
databas
see
refer
detail
darunavir
relat
inhibitor
group
also
quit
potent
prepar
correspond
ligand
result
inhibitor
show
stereochem
prefer
potenc
similar
correspond
hydroxi
deriv
determin
xray
crystal
structur
proteas
resolut
shown
figur
cpthf
ring
oxygen
form
strong
hydrogen
bond
nh
group
rather
weak
hydrogen
bond
carboxyl
group
appear
form
nice
watermedi
hydrogen
bond
backbon
nh
group
pi
evalu
panel
multidrugresist
variant
compar
approv
pi
darunavir
apv
tabl
activ
inhibitor
variou
multidrugresist
variant
similar
darunavir
chang
ic
valu
similar
darunavir
contrast
pi
ligand
lost
potenc
significantli
also
apv
show
high
ic
valu
lower
resili
drugresist
strain
examin
xray
structur
proteas
resist
profil
support
backbonebind
strategi
combat
drug
resist
deriv
pi
site
probe
effect
drugresist
properti
addit
ligand
design
enhanc
interact
protein
backbon
subsit
also
expand
design
concept
region
proteas
activ
site
particularli
plan
design
pi
new
ligand
place
isobutyl
group
could
interact
backbon
atom
well
fill
hydrophob
pocket
subsit
explor
incorpor
stereochem
defin
oxazolidinon
function
pyrrolidinon
nh
group
could
form
hydrogen
bond
carbonyl
group
could
interact
site
initi
plan
examin
potenti
new
ligand
combin
cpthf
bisthf
ligand
also
want
address
question
whether
enhanc
backbonebind
interact
would
lead
pi
improv
drugresist
profil
result
investig
summar
figur
inhibitor
ligand
show
good
enzym
inhibitori
potenc
antivir
ic
valu
nm
r
deriv
show
improv
k
valu
antivir
activ
ic
nm
rel
spyrrolidin
deriv
combin
bisthf
r
ligand
howev
antivir
activ
significantli
less
antivir
potenc
nearli
ten
time
less
possibl
result
poor
cellular
permeabl
polar
function
nevertheless
inhibitor
potent
inhibitor
antivir
activ
compar
fdaapprov
pi
idv
apv
lpv
amino
acid
substitut
identifi
proteaseencod
region
compar
consensu
type
b
sequenc
cite
lo
alamo
databas
see
refer
detail
obtain
molecular
insight
variou
ligand
bind
site
interact
determin
highresolut
xray
crystal
structur
proteas
resolut
shown
figur
interact
inhibitor
activ
site
quit
extens
strikingli
exist
two
conform
one
conform
pyrrolidinon
nh
group
engag
hydrogen
bond
carbonyl
pyrrolidinon
carbonyl
form
watermedi
hydrogen
bond
side
chain
anoth
conform
pyrrolidinon
ligand
fill
hydrophob
pocket
carbonyl
group
make
weak
hydrogen
bond
backbon
nh
group
bind
interact
cpthf
ligand
site
similar
methoxi
oxygen
form
strong
hydrogen
bond
backbon
nh
group
sidechain
carboxyl
group
inhibitor
evalu
wide
spectrum
laboratori
clinic
wildtyp
multidrugresist
strain
tabl
show
antihiv
activ
select
clinic
isol
highli
resist
multipl
pi
seen
inhibitor
highli
potent
variou
clinic
isol
test
except
darunavir
approv
pi
fail
exert
compar
activ
howev
inhibitor
like
darunavir
potent
inhibit
seven
primari
strain
particularli
maintain
nearli
full
potenc
except
phenotyp
lost
potenc
slightli
less
twofold
overal
interact
inhibitor
backbon
atom
particularli
subsit
enhanc
compar
inhibitor
polar
interact
conform
flexibl
oxazolidinon
like
contribut
robust
activ
multidrugresist
variant
follow
explor
pi
base
meso
ligand
continu
examin
way
could
reduc
stereochem
complex
bisthf
ligand
maintain
key
backbon
interact
accommod
variat
amino
acid
side
chain
within
activ
site
occur
viral
mutat
probe
turn
cyclicpolyetherderiv
ligand
system
possess
flexibl
ring
capabl
repack
within
bind
pocket
respons
mutat
chang
base
proposit
remov
share
c
c
bond
bisthf
produc
flexibl
eightmemberedr
inhibitor
shown
figur
unfortun
display
significantli
amino
acid
substitut
identifi
proteaseencod
region
tm
mm
c
g
compar
consensu
b
sequenc
cite
lo
alamo
databas
see
refer
lower
enzym
inhibitori
potenc
darunavir
reduc
ring
size
sevenmemb
ring
restor
enzym
inhibitori
activ
prefer
r
stereoisom
reveal
correspond
pi
epimer
ligand
display
signific
loss
potenc
k
nm
ic
nm
reduct
ring
size
led
sixmemberedr
inhibitor
also
highli
potent
gener
expand
ring
larger
polycycl
ether
tenmemb
ring
larger
result
drastic
loss
potenc
ether
oxygen
within
ring
system
critic
maintain
high
level
enzym
inhibit
activ
remov
either
oxygen
result
signific
loss
activ
xray
crystal
structur
proteas
determin
resolut
major
bind
interact
within
activ
site
similar
natur
inhibitor
except
interact
site
shown
figur
one
oxygen
ligand
involv
hydrogen
bond
nh
group
oxygen
involv
uniqu
interact
nh
group
water
molecul
pi
evalu
antivir
activ
panel
clinic
relev
isol
tabl
less
potent
darunavir
compound
outperform
approv
pi
rtv
idv
compar
antivir
activ
apv
result
suggest
abil
ligand
maintain
hydrogenbond
interact
protein
backbon
may
respons
improv
drugresist
profil
pi
examin
design
pi
use
concept
maxim
backbon
bind
led
pi
character
high
potenc
wildtyp
multidrugresist
strain
optim
bisthf
ligand
design
tpthf
ligand
subsequ
evalu
option
improv
upon
bisthf
ligand
darunavir
analysi
xray
structur
darunavirbound
proteas
figur
reveal
bisthf
ether
oxygen
involv
hydrogenbond
interact
amid
nh
group
distanc
respect
conceptu
incorpor
larger
ring
system
might
promot
closer
effect
hydrogen
bond
backbon
residu
result
favor
align
cyclic
ether
oxygen
amid
nh
bond
factor
might
result
stronger
hydrogen
bond
higher
affin
inhibitor
addit
larger
ring
size
may
promot
favor
hydrophob
interact
within
subsit
allow
addit
flexibl
better
accommod
steric
chang
caus
proteas
mutat
therefor
synthes
evalu
seri
pi
contain
tetrahydropyranylthf
tpthf
ligand
shown
figur
consist
bisthf
bicycl
ligand
configur
effect
epimer
ligand
like
bisthf
ligand
cyclic
ether
oxygen
critic
bind
respect
replac
methylen
group
result
signific
loss
potenc
also
prepar
pi
incorpor
pmethoxybenzyl
side
chain
ligand
pmethoxysulfonamid
paminophenylsulfonamid
ligand
respect
detail
drugresist
studi
show
pi
potent
multipiresist
variant
obtain
molecular
insight
creat
activ
model
start
xray
crystal
structur
conform
optim
use
amino
acid
substitut
identifi
proteaseencod
region
compar
consensu
type
b
sequenc
cite
lo
alamo
databas
see
refer
chemi
forc
field
appear
cyclic
ether
oxygen
tpthf
within
hydrogenbond
distanc
backbon
nh
group
subsit
activesit
interact
similar
xray
structur
proteas
depict
tabl
panel
multidrugresist
clinic
isol
inhibitor
outperform
two
approv
pi
apv
lpv
display
high
level
antivir
activ
strain
ec
valu
rang
nm
result
compar
potent
darunavir
absolut
term
howev
fold
chang
efficaci
factor
viral
strain
similar
effort
target
protein
backbon
design
strategi
combat
drug
resist
develop
varieti
intrigu
ligand
scaffold
gener
divers
inhibitor
except
potenc
drugresist
profil
next
object
optim
ligand
structur
could
maintain
critic
backbon
interact
time
effect
fill
hydrophob
pocket
activ
site
maxim
proteinligand
interact
toward
object
elect
append
function
bisthf
ligand
improv
drugresist
properti
pi
shown
figur
base
upon
overlay
xray
structur
darunavirbound
sqvbound
proteas
plan
fill
hydrophob
pocket
occupi
quinald
moieti
sqv
particularli
specul
fusion
anoth
tetrahydrofuran
ring
bisthf
ligand
would
provid
addit
ligand
bind
site
interact
oxatricycl
ligand
could
number
possibl
stereochem
motif
includ
synsynsyn
ssstype
synantisyn
sastyp
isom
model
base
upon
overlay
structur
figur
suggest
sastyp
ligandbas
inhibitor
would
make
enhanc
interact
subsit
subsequ
synthes
sasand
sssoxatricycl
ligand
stereoselect
manner
prepar
respect
pi
shown
figur
inhibitor
synantisyn
configur
tristhf
ring
exhibit
tenfold
better
enzym
inhibitori
potenc
synsynsyn
deriv
inhibitor
also
display
better
antivir
activ
xray
structur
proteas
determin
figur
analysi
structur
reveal
detail
amino
acid
substitut
identifi
proteaseencod
region
b
c
g
tm
mm
jsl
assay
protocol
see
refer
wwwangewandteorg
number
addit
interact
within
subsit
seen
bisthf
unit
darunavir
two
top
thf
ring
oxygen
involv
hydrogenbond
interact
backbon
nh
group
second
thf
oxygen
appear
form
hydrogen
bond
carboxyl
side
chain
expect
third
thf
ring
fill
subsit
nice
third
thf
ring
also
particip
semicircular
hydrogenbond
network
three
conserv
water
molecul
surround
guanidin
side
chain
inhibitor
prove
extrem
potent
variou
multidrugresist
variant
ic
valu
rang
nm
nearli
improv
potenc
darunavir
tabl
emerg
vitro
substanti
delay
compar
select
approv
pi
also
strikingli
potent
block
proteas
dimer
least
factor
compar
darunavir
examin
fluoresc
reson
energi
transfer
base
express
assay
employ
cyan
yellow
fluoresc
protein
tag
proteas
monom
present
data
suggest
class
pi
may
develop
potenti
therapeut
agent
treatment
primari
multidrugresist
infect
specif
interest
chemistri
biolog
natur
product
brought
uniqu
perspect
design
synthesi
proteas
inhibitor
treatment
hiv
infect
aid
initi
academ
pursuit
focus
address
question
whether
could
design
natur
product
deriv
ligand
templat
could
mimic
biolog
mode
action
peptid
bond
allevi
problem
inher
peptidebas
drug
natur
optim
variou
cyclic
etherpolycycl
ether
templat
million
year
variou
biolog
microenviron
involv
biosynthet
enzym
inspir
natur
base
upon
xray
structur
proteinligand
complex
invok
idea
design
stereochem
defin
cyclic
ether
polyetherlik
molecular
featur
replac
peptid
bond
effect
fill
hydrophob
pocket
activ
site
proteas
envis
posit
cyclic
ether
oxygen
mimic
biolog
action
peptid
carbonyl
group
cyclic
function
would
make
necessari
van
der
waal
interact
hydrophob
pocket
research
effort
led
creation
varieti
conceptu
novel
molecular
templat
entir
nonpeptid
interact
proteas
remark
affin
mani
xray
structur
studi
inhibitorbound
proteas
provid
strong
evid
cyclic
etherpolyeth
oxygen
inde
serv
effect
mimic
carbonyl
peptideamid
function
also
cyclic
unit
nice
fill
hydrophob
pocket
enzym
activ
site
follow
develop
variou
nonpeptid
highaffin
ligand
turn
toward
address
issu
drug
resist
interest
optim
inhibitor
structur
wildtyp
proteas
well
known
mutant
proteas
object
led
us
examin
xray
structur
inhibitorbound
wildtyp
proteas
well
xray
structur
number
mutant
proteas
superimposit
xray
structur
evidenc
minim
distort
backbon
conform
led
proposit
target
protein
backbon
strategi
evad
drug
resist
maxim
hydrogenbond
interact
protein
backbon
essenti
creat
molecular
crab
capabl
latch
hold
tightli
enzym
activ
site
figur
xray
structur
hiv
proteas
pdb
code
see
refer
detail
use
combin
indepth
antivir
studi
along
drugresist
xray
crystallograph
studi
document
practic
use
backbonebind
design
strategi
combat
drug
resist
combin
liganddesign
effort
inspir
polyeth
natur
product
subsequ
inhibitor
design
effort
target
proteas
backbon
combat
drug
resist
culmin
discoveri
ultim
develop
darunavir
first
fdaapprov
treatment
patient
multidrugresist
variant
indic
later
gener
patient
hiv
infect
aid
furthermor
discov
darunavir
possess
dual
mechan
action
potent
inhibitor
proteas
dimer
discoveri
darunavir
mark
import
turn
point
paradigm
design
hiv
pi
work
led
us
develop
backbonebind
concept
effect
mean
mitig
viral
adapt
continu
appli
backbonebind
design
strategi
result
design
synthesi
varieti
exceedingli
potent
proteas
inhibitor
intrigu
structur
featur
interestingli
retain
near
full
potenc
panel
multidrugresist
variant
also
design
mark
tenfold
improv
antivir
activ
darunavir
retent
potenc
wide
rang
clinic
relev
multidrugresist
strain
backbonebind
concept
may
prove
use
guid
design
antiretrovir
agent
area
well
continu
util
develop
concept
futur
design
strive
meet
challeng
today
medicin
work
support
nation
institut
health
thank
dr
k
v
rao
purdu
univers
help
discuss
